Bcl2

Washington

InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China

[ad_1] BEIJING–(BUSINESS WIRE)–Mar 9, 2023– InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of…

Read More »
Back to top button
Close